Monteresearch is strongly committed with the development of a patient-centric R&D Pipeline focused on repositioning of known drug substances to address unmet medical needs through specific Oral Drug Delivery and Dosage Form customization.

Drugs repositioning follow the regulatory pattern of Hybrid Application by EMA and / or 505(b)(2) by FDA, by exploiting the well-established patients’ safety of already marketed Drug Substances, hence shortening their time-to-market.

Dosage forms such as delayed or modified release tablets and/or capsules, pellets or granules may be developed to deliver the payload to the distal gut regions as well as gastro-retentive formulations to deal with pathologies of the stomach or early duodenum.

The deep expertise accumulated through world class knowledge around the development of these dosage forms, lead us to select and design the most appropriate Target Product Profile for clinical development.

Along with the repositioning of existing drugs for new / unmet gastro-intestinal diseases, Monteresearch is committed to develop Oral Peptides and Oligos overcoming their well-known absorption limitations, thanks to the design the most appropriate Drug Delivery System ensuring good bioavailability and stability in a context of improved patients’ compliance and differentiation.